[
  {
    "ts": "2025-11-05T07:07:34+00:00",
    "headline": "Novo Cuts Outlook Citing Lower Wegovy, Ozempic Sales",
    "summary": "Novo Nordisk pared its forecast for a fourth time this year, citing lower-than-anticipated sales of its blockbuster drugs Wegovy and Ozempic. The Danish drugmaker is struggling to compete with Eli Lilly in the growing market for obesity medicines. Bloomberg's Sara Sjolin reports.",
    "url": "https://finance.yahoo.com/video/novo-cuts-outlook-citing-lower-070734151.html",
    "source": "Bloomberg",
    "provider": "yfinance",
    "raw": {
      "id": "a154678e-5ee0-36f7-bb14-614a98d2e1f0",
      "content": {
        "id": "a154678e-5ee0-36f7-bb14-614a98d2e1f0",
        "contentType": "VIDEO",
        "title": "Novo Cuts Outlook Citing Lower Wegovy, Ozempic Sales",
        "description": "Novo Nordisk pared its forecast for a fourth time this year, citing lower-than-anticipated sales of its blockbuster drugs Wegovy and Ozempic. The Danish drugmaker is struggling to compete with Eli Lilly in the growing market for obesity medicines. Bloomberg's Sara Sjolin reports.",
        "summary": "Novo Nordisk pared its forecast for a fourth time this year, citing lower-than-anticipated sales of its blockbuster drugs Wegovy and Ozempic. The Danish drugmaker is struggling to compete with Eli Lilly in the growing market for obesity medicines. Bloomberg's Sara Sjolin reports.",
        "pubDate": "2025-11-05T07:07:34Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/bloomberg_markets_video_2/48da09b73e617d3ed4db23762a76e6c5",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1zybb2vgGgXBzqNJ7szMrA--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/bloomberg_markets_video_2/48da09b73e617d3ed4db23762a76e6c5.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YicD43sE6CI_pRnJke6u5g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/bloomberg_markets_video_2/48da09b73e617d3ed4db23762a76e6c5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Bloomberg",
          "url": "https://www.bloomberg.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/novo-cuts-outlook-citing-lower-070734151.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/novo-cuts-outlook-citing-lower-070734151.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]